Quantitative Determination of Epa and Dha in Fish Oil Capsules for Cardiovascular Disease Therapy in Indonesia by Gc-Ms
Authors:
Open Access
- 15 April 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Public Health Research
- Vol. 10 (2)
Abstract
Background: The consumption of EPA (Eicosapentaenoic acid), and DHA (docosahexaenoic acid), from fish oil, in the long run, has been observed to have a positive impact on patients with coronary heart disease. Fish oil products, with so much EPA and DHA content are available, and have very variable prices. Therefore, as a therapy to be used for long-term treatment, the cost factor is to be considered. Design and methods: This study analyzed the content of EPA and DHA, using GC-MS. The sample to be analyzed was the fish oil that has the lowest price (Product A1), and that of the highest (Product A2). Furthermore, the macroscopic analysis was performed, by observing the physical form including organoleptic and qualitative tests, by reading the fragments identified by EPA and DHA. Results: Clinical trials were conducted on patients (about 46 people), with risk factors and dyslipidemia. Product A1 showed EPA at tR= 15.574 min (relative%= 88.49%, similarity= 95%), and DHA at tR= 21.714 min (relative%= 88.92%, similarity= 93%). Product A2 showed EPA at tR= 28.719 min (relative%= 22.58%, similarity= 89%), and DHA at tR= 32.327 min (relative%= 22.87%, similarity= 90%), which meant that both had EPA and DHA contents, in accordance with their labels. Both products were confirmed to reduce total cholesterol in 4weeks (p=0.000, p= 0.000), with no significant difference in their effectiveness (p=0.652). Conclusion: The results showed that both the A1 and A2 products, had the EPA and DHA contents in accordance with their respective labels. However, with the A2 product having a percentage relatively higher than that of the A1 brand, both are equally very effective.Keywords
This publication has 28 references indexed in Scilit:
- Race–Sex Differences in the Management of HyperlipidemiaAmerican Journal of Preventive Medicine, 2015
- Comparative analysis of EPA and DHA in fish oil nutritional capsules by GC-MSLipids in Health and Disease, 2014
- Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled studyLipids in Health and Disease, 2014
- Cardiovascular Disease Risk Assessment: Insights from FraminghamGlobal Heart, 2013
- Omega-3 fatty acid supplementation and cardiovascular diseaseJournal of Lipid Research, 2012
- Lipid Metabolism and Toxicity in the HeartCell Metabolism, 2012
- Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout LifeAdvances in Nutrition, 2012
- Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive surveyDrug Design, Development and Therapy, 2011
- Analysis of eicosapentaenoic and docosahexaenoic acid geometrical isomers formed during fish oil deodorizationJournal of Chromatography A, 2006
- Die Rolle des Lipidstoffwechsels in der Prävention der koronaren HerzerkrankungClinical Research in Cardiology, 2005